- Home
- MEDP
as 11-20-2025 3:26pm EST
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | CINCINNATI |
| Market Cap: | 13.4B | IPO Year: | 2016 |
| Target Price: | $465.18 | AVG Volume (30 days): | 250.1K |
| Analyst Decision: | Hold | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 14.32 | EPS Growth: | 25.36 |
| 52 Week Low/High: | $250.05 - $625.00 | Next Earning Date: | 10-22-2025 |
| Revenue: | $2,358,373,000 | Revenue Growth: | 13.88% |
| Revenue Growth (this year): | 21.48% | Revenue Growth (next year): | 11.90% |
Stock Insider Trading Activity of Medpace Holdings Inc. (MEDP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Troendle August J. | MEDP | CEO | Nov 19 '25 | Sell | $592.07 | 23,862 | $14,127,974.34 | 862,315 | |
| Troendle August J. | MEDP | CEO | Nov 18 '25 | Sell | $590.84 | 7,191 | $4,248,730.44 | 862,315 | |
| Troendle August J. | MEDP | CEO | Nov 17 '25 | Sell | $591.00 | 6,047 | $3,573,777.00 | 862,315 | |
| Kraft Robert O. | MEDP | Director | Nov 14 '25 | Sell | $591.85 | 6,472 | $3,830,453.20 | 833 | |
| Troendle August J. | MEDP | CEO | Nov 14 '25 | Sell | $595.26 | 14,747 | $8,778,299.22 | 862,315 | |
| Troendle August J. | MEDP | CEO | Nov 13 '25 | Sell | $601.37 | 5,128 | $3,083,825.36 | 862,315 | |
| Troendle August J. | MEDP | CEO | Nov 12 '25 | Sell | $603.23 | 5,312 | $3,204,357.76 | 862,315 | |
| BURWIG SUSAN E | MEDP | Exec. VP, Operations | Nov 11 '25 | Sell | $605.00 | 18,000 | $10,890,000.00 | 47,500 | |
| GEIGER JESSE J | MEDP | President | Nov 5 '25 | Sell | $595.66 | 21,503 | $12,808,476.98 | 15,000 | |
| DAVENPORT FRED B JR | MEDP | Director | Oct 30 '25 | Sell | $581.88 | 5,972 | $3,474,987.36 | 3,498 |
Latest Medpace Holdings Inc. News
MEDP Breaking Stock News: Dive into MEDP Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
Daily – Vickers Top Buyers & Sellers for 11/17/2025
MT Newswires
6 days ago
Medpace Holdings Insider Sold Shares Worth $6,288,183, According to a Recent SEC Filing
MT Newswires
9 days ago
Medpace Holdings Insider Sold Shares Worth $10,890,000, According to a Recent SEC Filing
Investor's Business Daily
a month ago
Stock Market Today: Dow Jones Index Starts To Gain As Tesla Dives On Earnings (Live Coverage)
Barchart
a month ago
Stocks Muted Before the Open With Earnings in Focus
Investor's Business Daily
a month ago
Medpace Rockets On 'Another Strong Q' That Includes A Guidance Hike
Zacks
a month ago
Medpace (MEDP) Beats Q3 Earnings and Revenue Estimates
Investing.com
a month ago
Medpace shares soar on blowout Q3 results, solid 2025 outlook
Compare MEDP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MEDP Medpace Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.